Evidence map›Paper›PMID 41576149›Full record

ArticlePloS one2026

HEDGES co-prevents both SARS-CoV-2 and pandemic influenza infection in mice by rapid, durable co-production of twelve different anti-pandemic monoclonal antibodies.

Marissa Mack, Alice Ye, Sarah Ursu, Ryan Ice, Liliana Soroceanu, Stan Shoor, Sean McAllister, Tim Heath, Chakkrapong Handumrongkul, Robert Debs

Abstract read
In one paragraph

Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Marissa MackDNARx, San Francisco, California, United States of America.
Alice YeDNARx, San Francisco, California, United States of America.
Sarah UrsuDNARx, San Francisco, California, United States of America.
Ryan IceDNARx, San Francisco, California, United States of America.
Liliana SoroceanuDNARx, San Francisco, California, United States of America.
Stan ShoorDNARx, San Francisco, California, United States of America.
Sean McAllisterDNARx, San Francisco, California, United States of America.
Tim HeathDNARx, San Francisco, California, United States of America.
Chakkrapong HandumrongkulDNARx, San Francisco, California, United States of America.
Robert DebsDNARx, San Francisco, California, United States of America.ORCID 0000-0001-9929-6267

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite all currently available anti-pandemic monoclonal-antibodies (mAbs) and vaccines, subsequently emerging pandemic-infections will likely become more pan-resistant-, -transmissible and/or -lethal. We have created HEDGES generation-2, a significantly more-combinatorial, -synergistic version of our generation-1 HEDGES DNA vector-based platform. We previously published that one safe intravenous injection of a HEDGES generation-1 DNA vector encoding one of three different FDA-approved mAbs produced durable therapeutic serum mAb levels as well as critical therapeutic endpoints in immunocompetent mice. Here we show one safe, intravenous administration of a 2nd-generation HEDGES DNA vector co-encoding four different anti-SARS-CoV-2 mAbs rapidly then durably co-produces high anti-SARS-CoV-2 mAb serum levels that effectively block SARS-CoV-2 virus binding to the ACE-2 spike protein in immunocompetent mice. In addition, four weekly intravenous HEDGES generation-2 DNA vector administrations co-encoding a total of ten-different anti-SARS-CoV-2 mAbs, 5J8, plus an anti-1918 pandemic influenza mAb and mepolizumab, an FDA-approved anti-IL-5 mAb, durably co-produce highly-neutralizing 5J8 anti-pandemic influenza mAb serum levels, as well as durably block SARS-CoV-2 virus-ACE-2 receptor binding in mice. Furthermore, unlike vaccines and mAbs, HEDGES does not require an intact cold chain and is readily freeze dried, enabling its prolonged storage at ambient temperatures worldwide, even in equatorial regions. Also, HEDGES can create, then deploy novel, more effective anti-pandemic mAbs ~three weeks after their identification. Conversely, vaccines require ~three months to deploy, recombinant-mAbs ~nine months. By rapidly then durably co-producing many different highly-neutralizing, highly-synergistic anti-pandemic mAbs, HEDGES may effectively co-prevent both SARS-CoV-2 and pandemic-influenza infections. HEDGES may also prevent even more-transmissible, -pan-resistant and/or -lethal pandemic diseases that subsequently-emerge.

Indexed as

Antibodies, MonoclonalAntibodies, ViralInfluenza, HumanOrthomyxoviridae InfectionsPandemicsAngiotensin-Converting Enzyme 2AnimalsCOVID-19FemaleGenetic VectorsHumansMiceSARS-CoV-2Spike Glycoprotein, CoronavirusAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID41576149
PMCPMC12829945

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.